Johnson & Johnson's Erleada Shows Improved Overall Survival In …
WEB9 hours ago — Johnson & Johnson's Erleada Shows Improved Overall Survival In Prostate Cancer Patients Compared To Pfizer's Drug. Wednesday, Johnson & Johnson (NYSE: JNJ) revealed results from a head-to-head...
ERLEADA® (apalutamide) demonstrates statistically significant and ...
WEB11 hours ago — Johnson & Johnson (NYSE: JNJ) today announced the results of a landmark real-world, head-to-head study showing that ERLEADA® (apalutamide) provided a statistically significant overall survival...
ERLEADA® (apalutamide) demonstrates statistically significant and ...
WEB1 day ago — ERLEADA ® (apalutamide) demonstrates statistically significant and clinically meaningful improvement in overall survival compared to enzalutamide in patients with metastatic castration-sensitive prostate cancer
Johnson & Johnson's Erleada Shows Improved Overall Survival
WEB9 hours ago — Johnson & Johnson reveals Erleada's 23% lower risk of death over Xtandi in a real-world study of prostate cancer patients, while also announcing a $2 billion biologics facility to support its...
JNJ's Erleada Shows Statistically Significant Overall Survival In ...
WEB9 hours ago — (RTTNews) - Johnson & Johnson (JNJ), Wednesday announced results from a head-to-head study, demonstrating statistically significant overall survival benefit in patients on Erleada at 24 months...
JNJ's Erleada Shows Statistically Significant Overall Survival In ...
WEB9 hours ago — Johnson & Johnson (JNJ), Wednesday announced results from a head-to-head study, demonstrating statistically significant overall survival benefit in patients on Erleada at 24 months compared to Enzalutamide in patients with metastatic castration-sensitive prostate cancer.
2024-10-02 | ERLEADA® (apalutamide) demonstrates statistically ...
WEB1 day ago — (2024-10-02 | NYSE:JNJ) ERLEADA® (apalutamide) demonstrates statistically significant and clinically meaningful improvement in overall survival compared to enzalutamide in patients with metastatic castration-sensitive prostate cancer
ERLEADA demonstrates statistically significant and clinically ...
WEBJohnson & Johnson today announced the results of a landmark real-world, head-to-head study showing that ERLEADA (apalutamide) provided a statistically significant overall survival benefit at 24 months compared to enzalutamide in patients with metastatic castration-sensitive prostate cancer (mCSPC).
Phase 2 data for ERLEADA® (apalutamide) plus androgen …
WEBSAN ANTONIO, May 3, 2024 – Johnson & Johnson announced today results from the open-label, single-arm Phase 2 Apa-RP study evaluating adjuvant treatment with ERLEADA ® (apalutamide) and androgen deprivation therapy (ADT) in patients with HRLPC who have undergone radical prostatectomy (RP).
J&J’s Erleada provides survival edge over Astellas’ Xtandi
WEB6 hours ago — The study looked at treatment outcomes for more than 3,700 patients and found that Erleada reduced the risk of death by 23% over Xtandi after 24 months, J&J said in a Tuesday release. The...